Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritised for inclusion in the core outcome set through a two-round Delphi survey completed by 1063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in five continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to 1) finalise the core outcome set and 2) prioritise a single measurement instrument to be used for evaluating each of the prioritised outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for at all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, the need for a higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimise some of the selected measurement instruments. The panel did not consider the prioritised set of outcomes and associated measurement instruments to be burdensome for patients and health professionals to use.

ERS statement: A core outcome set for clinical trials evaluating the management of COPD exacerbations / Mathioudakis, A. G.; Abroug, F.; Agusti, A.; Ananth, S.; Bakke, P.; Bartziokas, K.; Beghe, Bianca.; Bikov, A.; Bradbury, T.; Brusselle, G.; Cadus, C.; Coleman, C.; Contoli, M.; Corlateanu, A.; Corlateanu, O.; Criner, G. J.; Csoma, B.; Emelyanov, A.; Faner, R.; Romero, G. F.; Hammouda, Z.; Horvath, P.; Garcia, A. H.; Jacobs, M.; Jenkins, C.; Joos, G.; Kharevich, O.; Kostikas, K.; Lapteva, E.; Lazar, Z.; Leuppi, J. D.; Liddle, C.; Linnell, J.; Lopez-Giraldo, A.; Mcdonald, V. M.; Nielsen, R.; Papi, A.; Saraiva, I.; Sergeeva, G.; Sioutkou, A.; Sivapalan, P.; Stovold, E.; Wang, H.; Wen, F.; Yorke, J.; Williamson, P. R.; Vestbo, J.; Jensen, J. -U.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 59:5(2022), pp. N/A-N/A. [10.1183/13993003.02006-2021]

ERS statement: A core outcome set for clinical trials evaluating the management of COPD exacerbations

Beghe Bianca.;
2022

Abstract

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritised for inclusion in the core outcome set through a two-round Delphi survey completed by 1063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in five continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to 1) finalise the core outcome set and 2) prioritise a single measurement instrument to be used for evaluating each of the prioritised outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for at all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, the need for a higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimise some of the selected measurement instruments. The panel did not consider the prioritised set of outcomes and associated measurement instruments to be burdensome for patients and health professionals to use.
2022
59
5
N/A
N/A
ERS statement: A core outcome set for clinical trials evaluating the management of COPD exacerbations / Mathioudakis, A. G.; Abroug, F.; Agusti, A.; Ananth, S.; Bakke, P.; Bartziokas, K.; Beghe, Bianca.; Bikov, A.; Bradbury, T.; Brusselle, G.; Cadus, C.; Coleman, C.; Contoli, M.; Corlateanu, A.; Corlateanu, O.; Criner, G. J.; Csoma, B.; Emelyanov, A.; Faner, R.; Romero, G. F.; Hammouda, Z.; Horvath, P.; Garcia, A. H.; Jacobs, M.; Jenkins, C.; Joos, G.; Kharevich, O.; Kostikas, K.; Lapteva, E.; Lazar, Z.; Leuppi, J. D.; Liddle, C.; Linnell, J.; Lopez-Giraldo, A.; Mcdonald, V. M.; Nielsen, R.; Papi, A.; Saraiva, I.; Sergeeva, G.; Sioutkou, A.; Sivapalan, P.; Stovold, E.; Wang, H.; Wen, F.; Yorke, J.; Williamson, P. R.; Vestbo, J.; Jensen, J. -U.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 59:5(2022), pp. N/A-N/A. [10.1183/13993003.02006-2021]
Mathioudakis, A. G.; Abroug, F.; Agusti, A.; Ananth, S.; Bakke, P.; Bartziokas, K.; Beghe, Bianca.; Bikov, A.; Bradbury, T.; Brusselle, G.; Cadus, C.; Coleman, C.; Contoli, M.; Corlateanu, A.; Corlateanu, O.; Criner, G. J.; Csoma, B.; Emelyanov, A.; Faner, R.; Romero, G. F.; Hammouda, Z.; Horvath, P.; Garcia, A. H.; Jacobs, M.; Jenkins, C.; Joos, G.; Kharevich, O.; Kostikas, K.; Lapteva, E.; Lazar, Z.; Leuppi, J. D.; Liddle, C.; Linnell, J.; Lopez-Giraldo, A.; Mcdonald, V. M.; Nielsen, R.; Papi, A.; Saraiva, I.; Sergeeva, G.; Sioutkou, A.; Sivapalan, P.; Stovold, E.; Wang, H.; Wen, F.; Yorke, J.; Williamson, P. R.; Vestbo, J.; Jensen, J. -U.
File in questo prodotto:
File Dimensione Formato  
ERS statement_a core outcome set for clinical trials evaluating.pdf

Accesso riservato

Descrizione: Articolo
Tipologia: Versione pubblicata dall'editore
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1280579
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 30
social impact